Corneal gene delivery: Chitosan oligomer as a carrier of CpG rich, CpG free or S/MAR plasmid DNA

Journal of Gene Medicine

Volumn 14, Issue 2, 2012, Pages 100-108

  Klausner, Eytan A ^a,b   Zhang, Zhong ^b   Wong, Suet P ^c   Chapman, Robert L ^b   Volin, Michael V ^d   Harbottle, Richard P ^c  

^a South College School of Pharmacy   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MIDWESTERN UNIVERSITY   (United States)

Author keywords

Corneal gene therapy; CpG free plasmid DNA; Nonviral gene delivery; Plasmid design; S MAR plasmid DNA; Ultrapure chitosan oligomers

Indexed keywords

CHITOSAN; GREEN FLUORESCENT PROTEIN; NANOPARTICLE; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL STRAIN COS7; CONTROLLED STUDY; CORNEA; CORNEAL GENE DELIVERY; CPG ISLAND; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; MATRIX ATTACHMENT REGION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ANIMALS; CELLS, CULTURED; CHITOSAN; CORNEAL DISEASES; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE THERAPY; GREEN FLUORESCENT PROTEINS; LUCIFERASES; NANOPARTICLES; PLASMIDS; RATS; TRANSFECTION; TRANSGENES;

EID: 84863177498     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1634     Document Type: Article

References (40)

1. Grigsby CL, Leong KW. Balancing protection and release of DNA: tools to address a bottleneck of non-viral gene delivery. J R Soc Interface 2010; 7(Suppl 1): S67-S82.
2. Pack DW, Hoffman AS, Pun S, et al. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005; 4: 581-593.
3. Won YY, Sharma R, Konieczny SF. Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. J Control Release 2009; 139: 88-93.
4. Yew NS. Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev 2005; 57: 769-780.
5. Caselli E, Balboni PG, Incorvaia C, et al. Local and systemic inoculation of DNA or protein gB1s-based vaccines induce a protective immunity against rabbit ocular HSV-1 infection. Vaccine 2000; 19: 1225-1231.
6. Braun S. Muscular gene transfer using nonviral vectors. Curr Gene Ther 2008; 8: 391-405.
7. de la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 2008; 15: 668-676.
8. Lufino MM, Edser PA, Wade-Martins R. Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. Mol Ther 2008; 16: 1525-1538.
9. Pathak A, Patnaik S, Gupta KC. Recent trends in non-viral vector-mediated gene delivery. Biotechnol J 2009; 4: 1559-1572.
10. Navarro G, Maiwald G, Haase R, et al. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. J Control Release 2010; 146: 99-105.
11. Tolmachov O. Designing plasmid vectors. Methods Mol Biol 2009; 542: 117-129.
12. Intra J, Salem AK. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release 2008; 130: 129-138.
13. Klausner EA, Zhang Z, Chapman RL, et al. Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials 2010; 31: 1814-1820.
14. Schaffert D, Wagner E. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther 2008; 15: 1131-1138.
15. Williams JA, Luke J, Langtry S, et al. Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. Biotechnol Bioeng 2009; 103: 1129-1143.
16. Scheule RK. The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 2000; 44: 119-134.
17. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
18. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol Biol 2009; 542: 87-104.
19. Lesina E, Dames P, Rudolph C. The effect of CpG motifs on gene expression and clearance kinetics of aerosol administered polyethylenimine (PEI)-plasmid DNA complexes in the lung. J Control Release 2010; 143: 243-250.
20. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549-551.
21. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005; 6: 299-310.
22. Wong SP, Argyros O, Coutelle C, et al. Strategies for the episomal modification of cells. Curr Opin Mol Ther 2009; 11: 433-441.
23. Ehrhardt A, Peng PD, Xu H, et al. Optimization of cis-acting elements for gene expression from nonviral vectors in vivo. Hum Gene Ther 2003; 14: 215-225.
24. Argyros O, Wong SP, Niceta M, et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther 2008; 15: 1593-1605.
25. Klausner EA, Peer D, Chapman RL, et al. Corneal gene therapy. J Control Release 2007; 124: 107-133.
26. Jiang X, Zheng Y, Chen HH, et al. Dual-sensitive micellar nanoparticles regulate DNA unpacking and enhance gene-delivery efficiency. Adv Mater 2010; 22: 2556-2560.
27. Koping-Hoggard M, Varum KM, Issa M, et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther 2004; 11: 1441-1452.
28. Mohri K, Okuda T, Mori A, et al. Optimized pulmonary gene transfection in mice by spray-freeze dried powder inhalation. J Control Release 2010; 144: 221-226.
29. Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006; 5: 803-825.
30. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16: 280-289.
31. Endmann A, Baden M, Weisermann E, et al. Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. Vaccine 2010; 28: 3642-3649.
32. Jia F, Wilson KD, Sun N, et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010; 7: 197-199.
33. Yang Z, Zhu J, Sriadibhatla S, et al. Promoter- and strain-selective enhancement of gene expression in a mouse skeletal muscle by a polymer excipient Pluronic P85. J Control Release 2005; 108: 496-512.
34. Tsan MF, White JE, Pastore JN, et al. Pulmonary response to plasmid DNA and immunohistochemical localization of transgene expression. Exp Lung Res 1996; 22: 651-666.
35. Templeton NS. Nonviral delivery for genomic therapy of cancer. World J Surg 2009; 33: 685-697.
36. Davies LA, McLachlan G, Sumner-Jones SG, et al. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther 2008; 16: 1283-1290.
37. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009; 109: 259-302.
38. Numata K, Hamasaki J, Subramanian B, et al. Gene delivery mediated by recombinant silk proteins containing cationic and cell binding motifs. J Control Release 2010; 146: 136-143.
39. Gazdhar A, Bilici M, Pierog J, et al. In vivo electroporation and ubiquitin promoter - a protocol for sustained gene expression in the lung. J Gene Med 2006; 8: 910-918.
40. Coster DJ. Cornea. BMJ Books: London, 2002.